2023年8月22日 · Akten Ophthalmic Gel 3.5% is a topical, ocular anesthetic formulation for use in any ocular procedure that requires a topical anesthetic agent, including cataract surgery, refractive surgery, Lasik surgery, and intravitreal injection.

2022年4月19日 · AKTEN® is a local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.

AKTEN®（盐酸利多卡因眼用凝胶）3.5％是一种无菌，无防腐剂，单个患者使用眼用凝胶用于局部眼麻醉制剂。 盐酸利多卡因在化学上称为乙酰胺，分子式为C 14 H 22 N 2 O•HCl，分子量为270.8的2-（二乙氨基）-N-（2,6-二甲基苯基）一盐酸盐。 活性成分的结构式为： AKTEN® 含有35毫克每毫升的利多卡因盐酸盐作为活性成分。 AKTEN® 还包含羟丙甲纤维素，氯化钠，和注射用水作为1 mL管中配置的非活性成分。 AKTEN® 包含羟丙甲纤维素，氯化钠，和注射用水作 …

Akten®是一种局部麻醉剂，通过抑制脉冲引发和传导所需的离子通量来稳定神经元膜，从而进行局部麻醉作用。 麻醉通常发生在20秒至1分钟之间并持续5至30分钟。

AKTEN ® (lidocaine hydrochloride ophthalmic gel) 3.5% is a sterile, preservative-free, single-patient use ophthalmic gel preparation for topical ocular anesthesia. Lidocaine hydrochloride is designated chemically as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl) monohydrochloride with a molecular formula of C14H22N20 ∙ HCl and molecular ...

2021年11月15日 · AKTEN® (lidocaine hydrochloride ophthalmic gel), for ... These highlights do not include all the information needed to use AKTEN safely and effectively. See full prescribing information for AKTEN. The recommended dose of AKTEN is 2 drops applied to the ocular surface in the area of the planned procedure.

AKTEN® is a local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local...

2024年4月19日 · AKTEN ® contains 35 mg of lidocaine hydrochloride per mL as the active ingredient. AKTEN ® also contains Hypromellose, Sodium Chloride, and Water for Injection as inactive ingredients in the 1 mL tube

商品名:akten,活性成分:lidocaine hydrochloride,申请号:022221,申请人:thea pharma

Please refer to your supplemental new drug application (sNDA) dated and received November 16, 2021, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for...